Kevin Feeley Sells 895 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 895 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $33.33, for a total transaction of $29,830.35. Following the sale, the chief financial officer now owns 39,910 shares in the company, valued at approximately $1,330,200.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, September 3rd, Kevin Feeley sold 262 shares of GeneDx stock. The stock was sold at an average price of $31.71, for a total value of $8,308.02.
• On Monday, July 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $33.54, for a total value of $9,189.96.
• On Monday, June 17th, Kevin Feeley sold 2,646 shares of GeneDx stock. The stock was sold at an average price of $28.31, for a total transaction of $74,908.26.

GeneDx Price Performance

NASDAQ WGS traded up $1.59 on Wednesday, reaching $35.26. 344,758 shares of the stock traded hands, compared to its average volume of 396,852. GeneDx Holdings Corp. has a 12 month low of $1.16 and a 12 month high of $37.45. The company has a market cap of $921.06 million, a price-to-earnings ratio of -6.81 and a beta of 2.29. The firm’s fifty day simple moving average is $32.49 and its 200 day simple moving average is $22.21. The company has a quick ratio of 2.22, a current ratio of 2.38 and a debt-to-equity ratio of 0.27.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, July 30th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.15. GeneDx had a negative return on equity of 22.71% and a negative net margin of 48.21%. As a group, research analysts predict that GeneDx Holdings Corp. will post -0.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Oracle Investment Management Inc. raised its holdings in GeneDx by 531.7% during the 1st quarter. Oracle Investment Management Inc. now owns 1,126,607 shares of the company’s stock worth $10,286,000 after buying an additional 948,253 shares during the period. Driehaus Capital Management LLC purchased a new position in shares of GeneDx in the second quarter worth approximately $11,335,000. Assenagon Asset Management S.A. acquired a new stake in shares of GeneDx during the second quarter valued at approximately $9,575,000. Divisadero Street Capital Management LP acquired a new stake in shares of GeneDx during the second quarter valued at approximately $5,886,000. Finally, Gagnon Securities LLC lifted its position in shares of GeneDx by 59.3% in the 1st quarter. Gagnon Securities LLC now owns 556,305 shares of the company’s stock valued at $5,079,000 after acquiring an additional 207,027 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

WGS has been the subject of several recent analyst reports. Craig Hallum upped their target price on shares of GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Wells Fargo & Company initiated coverage on GeneDx in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $34.00 price objective for the company. BTIG Research lifted their target price on GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, July 31st. TD Cowen increased their price target on GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Finally, The Goldman Sachs Group lifted their price objective on shares of GeneDx from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.